The primary efficacy endpoint was change from baseline MADRS score. This short-term analyze located that, compared to intranasal placebo in addition oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant appreciably enhanced depressive signs right after 4 months by a suggest difference of four points about the MADRS. The https://zanej023fir1.wiki-jp.com/user